CCM
DRNA

Cadence Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Cadence Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-48,995
Closed -$1.24M – 415
2020
Q2 		$1.24M Sell
48,995
-39,764
-45% -$857K 0.18% 179
2020
Q1 		$1.63M Buy
+88,759
New +$1.73M 0.28% 99

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Cadence Capital Management's DRNA Position: Q3 2020 in Review

Cadence Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2020, closing a stake of 48,995 shares — an estimated $1.24M sold.

Cadence Capital Management first reported a position in DRNA in Q1 2020 and held it in 2 quarters. The position peaked at $1.63M in Q1 2020. 172 funds tracked by Wall St. Rank hold DRNA as of Q3 2020.

  • Cadence Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Cadence Capital Management sold 48,995 Dicerna Pharmaceuticals, Inc. shares in Q3 2020, an estimated $1.24M.
  • Cadence Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2020 and held it in 2 quarters.
  • Cadence Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $1.63M in Q1 2020.
  • 172 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2020.

Based on Cadence Capital Management's 13F filing for Q3 2020, filed 16 Oct 2020.